Collectively, these findings underscore the complex and multifaceted roles of IRF3 and IRF7 in MS pathogenesis, highlighting their potential as therapeutic targets for modulating neuroinflammation and immune responses. The gene discussed is IRF7; the disease is myeloid sarcoma.